Literature DB >> 2410408

Heparin-binding properties of human serum spreading factor.

D W Barnes, J E Reing, B Amos.   

Abstract

Human serum spreading factor (SF) is a blood glycoprotein that promotes attachment and spreading and influences growth, migration, and differentiation of a variety of animal cells in culture. SF purified from human plasma or serum by chromatographic methods reported previously (Barnes, D. W., and Silnutzer, J. (1983) J. Biol. Chem. 258, 12548-12552) does not bind to heparin-Sepharose under conditions of physiological ionic strength and pH. In a further examination of the heparin-binding properties of human serum SF, we found that exposure of purified SF to 8 M urea altered several properties of the protein, including heparin affinity, and these alterations remained after removal of the urea from SF solutions. Urea-treated SF bound to heparin under physiological conditions, and salt concentrations of 0.4 M or higher were required for elution of urea-treated SF from heparin-Sepharose at pH 7.0. The alteration of heparin-binding properties of SF also was observed upon exposure of the protein to heat or acid. Treatment of SF with urea, heat, or acid resulted additionally in greatly decreased cell spreading-promoting activity of the molecule. The decreased biological activity was associated with a reduced ability of the treated SF to bind to the cell culture substratum, a prerequisite for the attachment-promoting activity of the molecule. Experiments examining the heparin-binding properties of native SF in unfractionated human plasma indicated that the major portion of SF in blood did not bind to heparin under conditions of physiological ionic strength and pH.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2410408

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Sulfated polysaccharide-directed recruitment of mammalian host proteins: a novel strategy in microbial pathogenesis.

Authors:  T D Duensing; J S Wing; J P van Putten
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Increased levels of plasma vitronectin in severe psoriatic patients.

Authors:  T Nogita; M Kawashima
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

3.  Endogenous cleavage of the Arg-379-Ala-380 bond in vitronectin results in a distinct conformational change which 'buries' Ser-378, its site of phosphorylation by protein kinase A.

Authors:  D Chain; B Korc-Grodzicki; T Kreizman; S Shaltiel
Journal:  Biochem J       Date:  1991-03-01       Impact factor: 3.857

4.  Vitronectin-binding staphylococci enhance surface-associated complement activation.

Authors:  F Lundberg; T Lea; A Ljungh
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

5.  Vitronectin (serum spreading factor): its localisation in normal and fibrotic tissue.

Authors:  J T Reilly; J R Nash
Journal:  J Clin Pathol       Date:  1988-12       Impact factor: 3.411

Review 6.  The role of vitronectin as multifunctional regulator in the hemostatic and immune systems.

Authors:  K T Preissner
Journal:  Blut       Date:  1989-11

7.  Human and mouse S-protein mRNA detected in northern blot experiments and evidence for the gene encoding S-protein in mammals by Southern blot analysis.

Authors:  M Solem; A Helmrich; P Collodi; D Barnes
Journal:  Mol Cell Biochem       Date:  1991-02-02       Impact factor: 3.396

8.  New insights into heparin binding to vitronectin: studies with monoclonal antibodies.

Authors:  P Anne Underwood; Alan Kirkpatrick; Sue M Mitchell
Journal:  Biochem J       Date:  2002-07-01       Impact factor: 3.857

9.  Human endothelial cell attachment to and growth on polypyrrole-heparin is vitronectin dependent.

Authors:  B Garner; A J Hodgson; G G Wallace; P A Underwood
Journal:  J Mater Sci Mater Med       Date:  1999-01       Impact factor: 3.896

10.  Vitronectin binds to the gonococcal adhesin OpaA through a glycosaminoglycan molecular bridge.

Authors:  T D Duensing; J P Putten
Journal:  Biochem J       Date:  1998-08-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.